Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3294927 | 0.86 | LMNA (0.52) | LMNAKMT2ATHRBHPGDALDH1A1 | |
| SCHEMBL10341159 | 0.84 | LMNA (0.55) | LMNAKMT2ATHRBHPGDALDH1A1 | |
| SCHEMBL7938747 | 0.83 | TDP1 (0.52) | LMNAKMT2AHPGDALDH1A1KDM4E | |
| SCHEMBL3291681 | 0.81 | LMNA (0.47) | LMNAKMT2ATHRBHPGDALDH1A1 | |
| SCHEMBL3294020 | 0.80 | LMNA (0.47) | LMNAKMT2ATHRBHPGDALDH1A1 | |
| SCHEMBL3291381 | 0.80 | LMNA (0.47) | LMNAKMT2ATHRBHPGDALDH1A1 | |
| SCHEMBL3288275 | 0.80 | LMNA (0.47) | LMNAKMT2ATHRBHPGDALDH1A1 | |
| SCHEMBL3291387 | 0.80 | LMNA (0.47) | LMNAKMT2ATHRBHPGDALDH1A1 | |
| SCHEMBL3296347 | 0.80 | PIM1 (0.53) | LMNAKMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL1132860 | 0.79 | LMNA (0.46) | LMNAKMT2ATHRBHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718621-B2 | Macrolones—amino substituted quinolones | GLAXO GROUP LTD. (GB) | 2010-05-18 | — | — | US | disclosed |
| US-20090062218-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20080090773-A1 | Macrolones - Amino Substituted Quinolones | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| CN-101098881-A | Macrolones - amino substituted quinolones | GLAXO GROUP LTD (GB) | 2008-01-02 | — | — | CN | disclosed |
| EP-1824871-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| EP-1824870-A1 | MACROLONES - AMINO SUBSTITUTED QUINOLONES | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006050942-A1 | MACROLONES - AMINO SUBSTITUTED QUINOLONES | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006050940-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062218-A1 | MACROLONE COMPOUNDS | CYP51A1, MRPL21, MYD88 | LMNA 1055/4885KMT2A 3931/4885THRB 3014/4885 |
| US-20080090773-A1 | Macrolones - Amino Substituted Quinolones | MRPL21, Q6ZSR9, QARS1 | LMNA 1318/4885KMT2A 2845/4885THRB 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.